Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal.

Published bySára Kerekesné Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal."— Presentation transcript:

1 Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis  Muntasir M. Abdelaziz, MRCP, Jagdish L. Devalia, PhD, Omer A. Khair, MRCP, Hasan Bayram, MD, Andrew J. Prior, FRCS, Robert J. Davies, FRCP  Journal of Allergy and Clinical Immunology  Volume 101, Issue 3, Pages (March 1998) DOI: /S (98) Copyright © 1998 Mosby, Inc. Terms and Conditions

2 FIG. 1 Effect of 10-9 to 10-3 mol/L fexofenadine (A); to 10-3 mol/L fexofenadine plus eosinophils (B); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (C) on changes in electrical resistance of HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season. Results are expressed as percentage change in electrical resistance from baseline. SF-medium , serum-free medium; Fexo, fexofenadine; Eos, eosinophils; and LB, latex beads. (n = 6 for each set of experiments; *p < 0.05 for cultures treated with eosinophils plus latex beads vs cultures treated with eosinophils plus latex beads in the presence of 10-9 to 10-3 mol/L fexofenadine). Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

3 FIG. 2 Release of RANTES from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

4 FIG. 3 Release of IL-8 from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

5 FIG. 4 Release of GM-CSF from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

6 FIG. 5 Release of sICAM-1 from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

7 FIG. 6 ECP release from eosinophils after incubation with latex beads with or without HNEC (A) and latex beads with or without HNEC with or without to 10-3 mol/L fexofenadine (B). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

8 FIG. 7 Effect of HNEC conditioned medium (CM) with or without 10-9 to 10-3 mol/L fexofenadine (A) and serum-free medium with or without 0.01 to 1.0 μmol/L PAF (B) on eosinophil chemotaxis in vitro. Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; PAF, platelet activating factor; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

9 FIG. 8 Effect of HNEC-conditioned medium (CM) with or without 10-9 to 10-3 mol/L fexofenadine on adherence of eosinophils to human endothelial cells in vitro. Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology  , DOI: ( /S (98) ) Copyright © 1998 Mosby, Inc. Terms and Conditions

Download ppt "Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal."

Similar presentations

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Shin-Ichi Nishikawa, MD, PhD 

Shin-Ichi Nishikawa, MD, PhD 
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions  Francis Davoine, MSc, Sophie Lavigne, MSc, Jamila.

Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions  Francis Davoine, MSc, Sophie Lavigne, MSc, Jamila.
Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33  Paul E. Pfeffer, MRCP, Yin-Huai Chen, MSc, Grzegorz Woszczek, PhD, Nick C.

Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33  Paul E. Pfeffer, MRCP, Yin-Huai Chen, MSc, Grzegorz Woszczek, PhD, Nick C.
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Allergic Rhinitis and Its Impact on Asthma

Allergic Rhinitis and Its Impact on Asthma
Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: Comparison with airway eosinophils  Julie.

Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: Comparison with airway eosinophils  Julie.
Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors  Philippe Gosset,

Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors  Philippe Gosset,
The effect of omalizumab on nasal allergic inflammation

The effect of omalizumab on nasal allergic inflammation
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
The histamine-cytokine network in allergic inflammation

The histamine-cytokine network in allergic inflammation
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 
Histamine in the immune regulation of allergic inflammation

Histamine in the immune regulation of allergic inflammation
Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis 

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis 
Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A  Satoshi Matsukura, MD, Fumio Kokubu,

Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A  Satoshi Matsukura, MD, Fumio Kokubu,
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure  Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure  Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Similar presentations

Ads by Google